Cosciens Biopharma Stock Analysis
| CSCI Stock | 2.86 0.75 35.55% |
COSCIENS Biopharma is overvalued with Real Value of 2.39 and Hype Value of 2.9. The main objective of COSCIENS Biopharma stock analysis is to determine its intrinsic value, which is an estimate of what COSCIENS Biopharma is worth, separate from its market price. There are two main types of COSCIENS Biopharma's stock analysis: fundamental analysis and technical analysis.
The COSCIENS Biopharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and COSCIENS Biopharma's ongoing operational relationships across important fundamental and technical indicators.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in COSCIENS Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in world development indicators. COSCIENS Stock Analysis Notes
The company has price-to-book (P/B) ratio of 1.17. Some equities with similar Price to Book (P/B) outperform the market in the long run. COSCIENS Biopharma recorded a loss per share of 6.54. The entity had not issued any dividends in recent years. The firm had 1:4 split on the 3rd of May 2024. For more info on COSCIENS Biopharma go to https://www.cosciensbio.com.COSCIENS Biopharma Investment Alerts
| COSCIENS Biopharma is way too risky over 90 days horizon | |
| COSCIENS Biopharma appears to be risky and price may revert if volatility continues | |
| COSCIENS Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 13.78 M. Net Loss for the year was (15.31 M) with profit before overhead, payroll, taxes, and interest of 4.42 M. | |
| COSCIENS Biopharma generates negative cash flow from operations | |
| COSCIENS Biopharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Trading Advice - news.stocktradersdaily.com |
COSCIENS Largest EPS Surprises
Earnings surprises can significantly impact COSCIENS Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-27 | 2023-12-31 | -3.88 | -4.64 | -0.76 | 19 | ||
2023-05-09 | 2023-03-31 | -4.28 | -3.52 | 0.76 | 17 | ||
2023-11-09 | 2023-09-30 | -2.44 | -3.4 | -0.96 | 39 |
COSCIENS Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.64 M.COSCIENS Profitablity
The company has Profit Margin (PM) of (2.0) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.86) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.86.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.94) | (0.90) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (1.16) | (1.22) |
Management Efficiency
COSCIENS Biopharma has return on total asset (ROA) of (0.1664) % which means that it has lost $0.1664 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1308) %, meaning that it created substantial loss on money invested by shareholders. COSCIENS Biopharma's management efficiency ratios could be used to measure how well COSCIENS Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.46. The COSCIENS Biopharma's current Return On Capital Employed is estimated to increase to -0.9. As of now, COSCIENS Biopharma's Total Current Assets are increasing as compared to previous years.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.10 | 3.28 | |
| Tangible Asset Value | 21.4 M | 19 M | |
| Tangible Book Value Per Share | 5.10 | 5.35 | |
| Enterprise Value Over EBITDA | 0.51 | 0.54 | |
| Price Book Value Ratio | 0.54 | 0.52 | |
| Enterprise Value Multiple | 0.51 | 0.54 | |
| Price Fair Value | 0.54 | 0.52 | |
| Enterprise Value | -6.9 M | -6.6 M |
COSCIENS Biopharma showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Technical Drivers
As of the 19th of December, COSCIENS Biopharma shows the mean deviation of 5.66, and Risk Adjusted Performance of 0.0514. COSCIENS Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.COSCIENS Biopharma Price Movement Analysis
The output start index for this execution was fifty-nine with a total number of output elements of two. The Moving Average is predictive technique used to analyze COSCIENS Biopharma price data points by creating a series of averages of different subsets of COSCIENS Biopharma entire price series.
COSCIENS Biopharma Outstanding Bonds
COSCIENS Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. COSCIENS Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most COSCIENS bonds can be classified according to their maturity, which is the date when COSCIENS Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
COSCIENS Biopharma Predictive Daily Indicators
COSCIENS Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of COSCIENS Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
COSCIENS Biopharma Forecast Models
COSCIENS Biopharma's time-series forecasting models are one of many COSCIENS Biopharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary COSCIENS Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About COSCIENS Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how COSCIENS Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling COSCIENS shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as COSCIENS Biopharma. By using and applying COSCIENS Stock analysis, traders can create a robust methodology for identifying COSCIENS entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (1.59) | (1.51) | |
| Operating Profit Margin | (1.91) | (1.81) | |
| Net Loss | (1.11) | (1.17) | |
| Gross Profit Margin | 0.49 | 0.38 |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding COSCIENS Biopharma to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Headlines Timeline Now
Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
| All Next | Launch Module |
Complementary Tools for COSCIENS Stock analysis
When running COSCIENS Biopharma's price analysis, check to measure COSCIENS Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy COSCIENS Biopharma is operating at the current time. Most of COSCIENS Biopharma's value examination focuses on studying past and present price action to predict the probability of COSCIENS Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move COSCIENS Biopharma's price. Additionally, you may evaluate how the addition of COSCIENS Biopharma to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Commodity Directory Find actively traded commodities issued by global exchanges |